24484606	354	Bancroft EK	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.	European urology	2014	26
27184417	367	Bianchini G	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.	Nature reviews. Clinical oncology	2016	42
11301010	571	Cantor SB	BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function.	Cell	2001	199
15125843	571	Shiozaki EN	Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling.	Molecular cell	2004	75
19088202	580	Reid LJ	E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks.	Proceedings of the National Academy of Sciences of the United States of America	2008	53
25452441	580	Couch FJ	Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.	Journal of clinical oncology 	2015	60
7907678	672	Ford D	Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.	Lancet	1994	261
9145676	672	Struewing JP	The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.	The New England journal of medicine	1997	316
9443863	672	Parmigiani G	Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.	American journal of human genetics	1998	141
9701363	672	Lakhani SR	Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.	Journal of the National Cancer Institute	1998	119
10359546	672	Peto J	Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.	Journal of the National Cancer Institute	1999	148
10883018	672	Holschneider CH	Ovarian cancer: epidemiology, biology, and prognostic factors.	Seminars in surgical oncology	2000	105
11179017	672	Risch HA	Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.	American journal of human genetics	2001	166
11207349	672	Hedenfalk I	Gene-expression profiles in hereditary breast cancer.	The New England journal of medicine	2001	260
11257103	672	Welcsh PL	BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.	Human molecular genetics	2001	114
11320250	672	Ruffner H	Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.	Proceedings of the National Academy of Sciences of the United States of America	2001	96
11463009	672	Meijers-Heijboer H	Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.	The New England journal of medicine	2001	91
11710890	672	King MC	Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.	JAMA	2001	91
11857015	672	Antoniou AC	A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.	British journal of cancer	2002	106
12023992	672	Kauff ND	Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.	The New England journal of medicine	2002	167
12023993	672	Rebbeck TR	Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.	The New England journal of medicine	2002	204
12162889	672	Radmacher MD	A paradigm for class prediction using gene expression profiles.	Journal of computational biology 	2002	82
12237281	672	Thompson D	Cancer Incidence in BRCA1 mutation carriers.	Journal of the National Cancer Institute	2002	206
12483514	672	Jasin M	Homologous repair of DNA damage and tumorigenesis: the BRCA connection.	Oncogene	2002	94
12677558	672	Antoniou A	Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.	American journal of human genetics	2003	579
14576434	672	King MC	Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.	Science	2003	394
14981104	672	Rebbeck TR	Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.	Journal of clinical oncology 	2004	146
15041722	672	Foulkes WD	Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.	Clinical cancer research 	2004	76
15197194	672	Metcalfe K	Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2004	111
15367553	672	Warner E	Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.	JAMA	2004	146
15547178	672	Kennedy RD	The role of BRCA1 in the cellular response to chemotherapy.	Journal of the National Cancer Institute	2004	85
15784178	672	Dumitrescu RG	Understanding breast cancer risk -- where do we stand in 2005?	Journal of cellular and molecular medicine	2005	81
15910949	672	Leach MO	Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).	Lancet	2005	156
16014699	672	Tavtigian SV	Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.	Journal of medical genetics	2006	168
16137750	672	Finch A	Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.	Gynecologic oncology	2006	73
16144895	672	Nelson HD	Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.	Annals of internal medicine	2005	84
16234515	672	Eisen A	Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.	Journal of clinical oncology 	2005	79
16284991	672	Pal T	BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.	Cancer	2005	156
16397213	672	Elstrodt F	BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.	Cancer research	2006	68
16484695	672	Chen S	Characterization of BRCA1 and BRCA2 mutations in a large United States sample.	Journal of clinical oncology 	2006	70
16522644	672	Mathe E	Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods.	Nucleic acids research	2006	81
16522651	672	Deng CX	BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution.	Nucleic acids research	2006	120
16835424	672	Finch A	Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.	JAMA	2006	93
16912212	672	Malone KE	Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.	Cancer research	2006	64
17117391	672	Lee Y	A candidate precursor to serous carcinoma that originates in the distal fallopian tube.	The Journal of pathology	2007	198
17148771	672	Risch HA	Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.	Journal of the National Cancer Institute	2006	127
17416853	672	Chen S	Meta-analysis of BRCA1 and BRCA2 penetrance.	Journal of clinical oncology 	2007	280
17456833	672	Crum CP	Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.	Clinical medicine and research	2007	64
17761984	672	Callahan MJ	Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.	Journal of clinical oncology 	2007	100
17924331	672	Easton DF	A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.	American journal of human genetics	2007	131
18034184	672	Fackenthal JD	Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.	Nature reviews. Cancer	2007	108
18159056	672	John EM	Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.	JAMA	2007	104
18165636	672	Chetrit A	Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.	Journal of clinical oncology 	2008	79
18182601	672	Begg CB	Variation of breast cancer risk among BRCA1/2 carriers.	JAMA	2008	82
18268356	672	Kauff ND	Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.	Journal of clinical oncology 	2008	92
18342932	672	Folkins AK	A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.	Gynecologic oncology	2008	62
18349832	672	Antoniou AC	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.	British journal of cancer	2008	99
18458280	672	Warner E	Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer.	Annals of internal medicine	2008	79
18649131	672	Byrski T	Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.	Breast cancer research and treatment	2009	72
18779615	672	Atchley DP	Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.	Journal of clinical oncology 	2008	107
18955455	672	Tan DS	"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.	Journal of clinical oncology 	2008	101
19060844	672	Clarke B	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.	Modern pathology 	2009	60
19141781	672	Rebbeck TR	Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.	Journal of the National Cancer Institute	2009	128
19241424	672	Hall MJ	BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.	Cancer	2009	70
19298662	672	Young SR	The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.	BMC cancer	2009	55
19479960	672	Wittwer CT	High-resolution DNA melting analysis: advancements and limitations.	Human mutation	2009	78
19491823	672	Poley JW	The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.	The American journal of gastroenterology	2009	64
19553641	672	Fong PC	Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.	The New England journal of medicine	2009	840
19636370	672	Brown PO	The preclinical natural history of serous ovarian cancer: defining the target for early detection.	PLoS medicine	2009	57
19648928	672	Lim E	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.	Nature medicine	2009	454
19841585	672	Kurian AW	BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications.	Current opinion in obstetrics and gynecology	2010	41
19858402	672	Graeser MK	Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2009	52
19996028	672	Oktay K	Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.	Journal of clinical oncology 	2010	57
20008645	672	Byrski T	Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.	Journal of clinical oncology 	2010	108
20177395	672	Moynahan ME	Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis.	Nature reviews. Molecular cell biology	2010	267
20368571	672	Malone KE	Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.	Journal of clinical oncology 	2010	46
20400477	672	O'Donovan PJ	BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair.	Carcinogenesis	2010	70
20427433	672	Amir E	Assessing women at high risk of breast cancer: a review of risk assessment models.	Journal of the National Cancer Institute	2010	89
20516115	672	Lee MS	Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.	Cancer research	2010	40
20606085	672	Hennessy BT	Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.	Journal of clinical oncology 	2010	67
20609467	672	Tutt A	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.	Lancet	2010	389
20609468	672	Audeh MW	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.	Lancet	2010	309
20616022	672	Walsh T	Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2010	126
20810374	672	Domchek SM	Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.	JAMA	2010	187
21135251	672	Villarroel MC	Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.	Molecular cancer therapeutics	2011	65
21233401	672	Gonzalez-Angulo AM	Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.	Clinical cancer research 	2011	109
21324516	672	Zhang S	Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.	Gynecologic oncology	2011	52
21358336	672	Levy DE	Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk.	Genetics in medicine 	2011	55
21505135	672	Link DC	Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.	JAMA	2011	59
21717445	672	Schwartz MD	Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.	Cancer	2012	31
21987798	672	Konishi H	Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.	Proceedings of the National Academy of Sciences of the United States of America	2011	47
21990146	672	Spurdle AB	ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.	Human mutation	2012	45
21990299	672	Yang D	Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.	JAMA	2011	104
22193408	672	Roy R	BRCA1 and BRCA2: different roles in a common pathway of genome protection.	Nature reviews. Cancer	2011	216
22203755	672	Kaye SB	Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.	Journal of clinical oncology 	2012	94
22314128	672	Krepischi AC	Germline DNA copy number variation in familial and early-onset breast cancer.	Breast cancer research 	2012	31
22452356	672	Ledermann J	Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.	The New England journal of medicine	2012	200
22516946	672	Leongamornlert D	Germline BRCA1 mutations increase prostate cancer risk.	British journal of cancer	2012	30
22576213	672	Birkbak NJ	Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.	Cancer discovery	2012	44
22614657	672	Hartman AR	Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.	Cancer	2012	37
22933060	672	Popova T	Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.	Cancer research	2012	57
23099806	672	Iqbal J	The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers.	British journal of cancer	2012	33
23233716	672	Weitzel JN	Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.	Journal of clinical oncology 	2013	33
23257159	672	McLaughlin JR	Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.	Journal of the National Cancer Institute	2013	26
23257362	672	Verhaak RG	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.	The Journal of clinical investigation	2013	106
23269703	672	Domchek SM	Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer.	Cancer discovery	2013	29
23377543	672	Tang J	Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination.	Nature structural and molecular biology	2013	123
23558900	672	Lips EH	Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.	British journal of cancer	2013	33
23569316	672	Castro E	Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.	Journal of clinical oncology 	2013	59
23628597	672	Mavaddat N	Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.	Journal of the National Cancer Institute	2013	94
23810788	672	Sandhu SK	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.	The Lancet. Oncology	2013	84
23918944	672	Phillips KA	Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2013	27
23942203	672	Tarabeux J	Streamlined ion torrent PGM-based diagnostics: BRCA1 and BRCA2 genes as a model.	European journal of human genetics 	2014	21
24042365	672	Rosenberg SM	Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.	Annals of internal medicine	2013	27
24140203	672	Widschwendter M	The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.	The Lancet. Oncology	2013	25
24218601	672	Etemadmoghadam D	Synthetic lethality between CCNE1 amplification and loss of BRCA1.	Proceedings of the National Academy of Sciences of the United States of America	2013	31
24225019	672	Lee JM	PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.	Annals of oncology 	2014	55
24292448	672	Phelan CM	Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.	British journal of cancer	2014	23
24346285	672	Lee AJ	BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.	British journal of cancer	2014	21
24366376	672	Moyer VA	Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.	Annals of internal medicine	2014	57
24366442	672	Nelson HD	Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.	Annals of internal medicine	2014	33
24449235	672	Schwartz MD	Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.	Journal of clinical oncology 	2014	24
24478461	672	Laddha SV	Mutational landscape of the essential autophagy gene BECN1 in human cancers.	Molecular cancer research 	2014	37
24519767	672	Metcalfe K	Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.	BMJ	2014	23
24567435	672	Finch AP	Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.	Journal of clinical oncology 	2014	57
24618965	672	Dewey FE	Clinical interpretation and implications of whole-genome sequencing.	JAMA	2014	118
24675953	672	Couch FJ	Two decades after BRCA: setting paradigms in personalized cancer care and prevention.	Science	2014	57
24675954	672	Venkitaraman AR	Cancer suppression by the chromosome custodians, BRCA1 and BRCA2.	Science	2014	31
24824314	672	Friebel TM	Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.	Journal of the National Cancer Institute	2014	23
24947112	672	Heemskerk-Gerritsen BA	Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.	International journal of cancer	2015	16
25072261	672	Golan T	Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.	British journal of cancer	2014	24
25224030	672	Mersch J	Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.	Cancer	2015	25
25348513	672	Zhong Q	Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.	Clinical cancer research 	2015	19
25366685	672	Kaufman B	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.	Journal of clinical oncology 	2015	144
25398451	672	Candido-dos-Reis FJ	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.	Clinical cancer research 	2015	16
25454609	672	Castro E	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.	European urology	2015	16
25481791	672	Oza AM	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.	The Lancet. Oncology	2015	70
25673085	672	Dietze EC	Triple-negative breast cancer in African-American women: disparities versus biology.	Nature reviews. Cancer	2015	28
26187614	672	Kim G	FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.	Clinical cancer research 	2015	35
26426480	672	Armstrong J	Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.	JAMA oncology	2015	15
26757170	672	Siu AL	Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement.	Annals of internal medicine	2016	42
8589730	675	Tavtigian SV	The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.	Nature genetics	1996	133
12065746	675	Howlett NG	Biallelic inactivation of BRCA2 in Fanconi anemia.	Science	2002	276
22274685	675	Bolton KL	Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.	JAMA	2012	99
23165508	675	Barber LJ	Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.	The Journal of pathology	2013	40
23544012	675	Gaudet MM	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk.	PLoS genetics	2013	45
11745677	1026	Piek JM	Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.	The Journal of pathology	2001	132
17334996	1029	Jönsson G	High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.	Genes, chromosomes and cancer	2007	64
19593635	1029	Hollestelle A	Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.	Breast cancer research and treatment	2010	83
23601657	1029	Riaz M	miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.	Breast cancer research 	2013	38
23677068	1029	Sekido Y	Molecular pathogenesis of malignant mesothelioma.	Carcinogenesis	2013	32
24733792	1029	Kurian AW	Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.	Journal of clinical oncology 	2014	68
25479140	1029	Grant RC	Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.	Gastroenterology	2015	23
25503501	1029	Maxwell KN	Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.	Genetics in medicine 	2015	24
27114589	1029	Vasen H	Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.	Journal of clinical oncology 	2016	16
26761715	1080	Soukarieh O	Exonic Splicing Mutations Are More Prevalent than Currently Estimated and Can Be Predicted by Using In Silico Tools.	PLoS genetics	2016	17
19808869	1111	Bolderson E	Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair.	Clinical cancer research 	2009	64
24270682	1302	Bouwman P	Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?	Clinical cancer research 	2014	40
15761464	1499	Bell DA	Origins and molecular pathology of ovarian cancer.	Modern pathology 	2005	100
16033833	1956	Lakhani SR	Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.	Clinical cancer research 	2005	149
19596646	1956	Anders CK	Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.	Clinical breast cancer	2009	104
21233402	1956	Rosell R	Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.	Clinical cancer research 	2011	78
23000897	1956	Cancer Genome Atlas Network.	Comprehensive molecular portraits of human breast tumours.	Nature	2012	2327
23012302	1956	André F	Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.	Annals of oncology 	2012	58
26358176	1956	Dietel M	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	Cancer gene therapy	2015	25
18171422	2064	Reis-Filho JS	Triple negative tumours: a critical review.	Histopathology	2008	212
18487574	2064	Rakha EA	Basal-like breast cancer: a critical review.	Journal of clinical oncology 	2008	213
19008097	2064	Irvin WJ Jr	What is triple-negative breast cancer?	European journal of cancer	2008	77
20100965	2064	Silver DP	Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.	Journal of clinical oncology 	2010	209
20576095	2064	Jönsson G	Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.	Breast cancer research 	2010	65
20877296	2064	Carey L	Triple-negative breast cancer: disease entity or title of convenience?	Nature reviews. Clinical oncology	2010	180
22331459	2064	Stevens KN	19p13.1 is a triple-negative-specific breast cancer susceptibility locus.	Cancer research	2012	44
22817698	2064	Byrski T	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.	Breast cancer research 	2012	36
24829859	2064	Yadav BS	Systemic treatment strategies for triple-negative breast cancer.	World journal of clinical oncology	2014	24
25129345	2064	Byrski T	Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.	Breast cancer research and treatment	2014	31
25682074	2064	Wong-Brown MW	Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.	Breast cancer research and treatment	2015	17
25847929	2064	Telli ML	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.	Journal of clinical oncology 	2015	27
25896973	2064	Chantrill LA	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial.	Clinical cancer research 	2015	25
19622404	2175	Thompson LH	Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights.	Mutation research	2009	61
15661754	2177	Howlett NG	The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability.	Human molecular genetics	2005	88
16116422	2177	Meetei AR	A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M.	Nature genetics	2005	179
26085575	2177	Virts EL	AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia.	Human molecular genetics	2015	19
21720365	2305	Cancer Genome Atlas Research Network.	Integrated genomic analyses of ovarian carcinoma.	Nature	2011	1665
22617326	2305	Szabova L	Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.	Cancer research	2012	34
23012305	2475	Crown J	Emerging targeted therapies in triple-negative breast cancer.	Annals of oncology 	2012	47
15485900	2547	Stark JM	Genetic steps of mammalian homologous repair with distinct mutagenic consequences.	Molecular and cellular biology	2004	156
25238946	2956	Lancaster JM	Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.	Gynecologic oncology	2015	24
26720728	2956	Norquist BM	Inherited Mutations in Women With Ovarian Carcinoma.	JAMA oncology	2016	24
18158901	3014	Xie A	Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian double-strand break repair.	Molecular cell	2007	101
21035408	3014	Bekker-Jensen S	Assembly and function of DNA double-strand break repair foci in mammalian cells.	DNA repair	2010	106
25514803	3265	Lo Iacono M	Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.	Journal of thoracic oncology 	2015	21
21435948	3845	Paranjape T	A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.	The Lancet. Oncology	2011	44
12060695	4292	Schouten JP	Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.	Nucleic acids research	2002	497
25980754	4595	Yurgelun MB	Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.	Gastroenterology	2015	18
11313470	4683	Xu B	Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation.	Molecular and cellular biology	2001	142
11809797	4683	Xu B	Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation.	Molecular and cellular biology	2002	129
12509764	4683	D'Andrea AD	The Fanconi anaemia/BRCA pathway.	Nature reviews. Cancer	2003	214
23468639	4683	Wang H	The interaction of CtIP and Nbs1 connects CDK and ATM to regulate HR-mediated double-strand break repair.	PLoS genetics	2013	42
26017449	4763	Patch AM	Whole-genome characterization of chemoresistant ovarian cancer.	Nature	2015	123
25847936	5290	Isakoff SJ	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.	Journal of clinical oncology 	2015	43
22628410	5728	Martins FC	Evolutionary pathways in BRCA1-associated breast tumors.	Cancer discovery	2012	41
25190698	5728	Daly MB	Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.	Journal of the National Comprehensive Cancer Network 	2014	30
10446958	5888	Yuan SS	BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.	Cancer research	1999	139
22789542	5888	Schlacher K	A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2.	Cancer cell	2012	184
25472942	5888	Sawyer SL	Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.	Cancer discovery	2015	66
26261251	5888	Song H	Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.	Journal of clinical oncology 	2015	21
23535731	7015	Bojesen SE	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.	Nature genetics	2013	181
17936556	7157	Soussi T	Shaping genetic alterations in human cancer: the p53 mutation paradigm.	Cancer cell	2007	102
18757330	7157	Carlson JW	Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.	Journal of clinical oncology 	2008	70
22545102	8314	Njauw CN	Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.	PloS one	2012	44
23277170	8314	Murali R	Tumours associated with BAP1 mutations.	Pathology	2013	27
23709298	8314	Farley MN	A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.	Molecular cancer research 	2013	34
25380601	8314	Baumann F	Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.	Carcinogenesis	2015	23
18157161	10111	Shrivastav M	Regulation of DNA double-strand break repair pathway choice.	Cell research	2008	316
19092773	10111	Ripperger T	Breast cancer susceptibility: current knowledge and implications for genetic counselling.	European journal of human genetics 	2009	45
22006311	10111	Walsh T	Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2011	149
22048815	10111	Weigman VJ	Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.	Breast cancer research and treatment	2012	39
16473279	10563	Richardson AL	X chromosomal abnormalities in basal-like human breast cancer.	Cancer cell	2006	295
25642960	10721	Mateos-Gomez PA	Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination.	Nature	2015	69
11967536	11200	Meijers-Heijboer H	Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.	Nature genetics	2002	216
12094328	11200	Vahteristo P	A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.	American journal of human genetics	2002	86
15604286	11200	Hickson I	Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.	Cancer research	2004	422
16551709	11200	Walsh T	Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.	JAMA	2006	143
20364141	11200	Stolz A	The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells.	Nature cell biology	2010	52
24549055	11200	Castéra L	Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.	European journal of human genetics 	2014	39
24976383	11200	Ertych N	Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells.	Nature cell biology	2014	30
25186627	11200	Tung N	Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.	Cancer	2015	49
25288723	11200	Kiiski JI	Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	22
26270727	11200	Desmond A	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.	JAMA oncology	2015	24
26483394	11200	Hu C	Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients.	Cancer epidemiology, biomarkers and prevention 	2016	11
26510020	11200	Mateo J	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.	The New England journal of medicine	2015	128
26976419	11200	Tung N	Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.	Journal of clinical oncology 	2016	10
27433846	11200	Pritchard CC	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.	The New England journal of medicine	2016	29
14576432	22976	Manke IA	BRCT repeats as phosphopeptide-binding modules involved in protein targeting.	Science	2003	230
18156967	57534	Jarboe E	Serous carcinogenesis in the fallopian tube: a descriptive classification.	International journal of gynecological pathology 	2008	56
21285249	79728	Casadei S	Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.	Cancer research	2011	55
14983014	164045	Cantor S	The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.	Proceedings of the National Academy of Sciences of the United States of America	2004	86
25945795	164045	Sun J	Mutations in RECQL Gene Are Associated with Predisposition to Breast Cancer.	PLoS genetics	2015	15
